


NEAT ID

EACS London 2021
29th October

Our Mission



To perform & coordinate Clinical Research on HIV/AIDS and associated Infectious Diseases at European and International levels.

To spread expertise and resources, provide training and mobility of scientists at all levels and & lasting research collaborations across Europe.

Who We are



What do NEAT ID do?

2 active studies currently recruiting/ 7 fully recruited



2 Studies in Pipeline

3 Studies in Set Up

Award NEAT ID "Integration" Grants

Current Study activity expected out to 2025



Planned collaborations with other organisations

NEAT ID In Numbers

Over **5000** patients recruited



Direct funding of research by NEAT ID: **5**



Number of countries involved – **21** and expanding

4 Covid-19 Studies

6 active HIV studies



25 Million in funding to sites

4 HIV studies completed

Number of sites involved – **150** and growing

Who We Work With



GILEAD

NHS

Chelsea and Westminster Hospital
NHS Foundation Trust



THERA
technologies



MASSACHUSETTS
GENERAL HOSPITAL

neatid

The European treatment
network for HIV, hepatitis
and global infectious diseases

HIV Clinical Trials Interventional Studies

Prof Georg Behrens

Chair of the NEAT ID Clinical Trial Committee

Completed Trials

NEAT 22

An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression

Sponsored By

Funded By

neatid | The European treatment network for HIV, hepatitis and global infectious diseases

ViiV
Healthcare

NEAT 22

Status: Recruitment Closed at 415 patients

Sites: 32

Countries: 6

Sub-Studies:

Cardiovascular Biomarker

Arterial Stiffness (endothelial function)

Carotid Intima Media Thickness (macrovascular disease)

Telemere

Publications: 4

Clinical Infectious Diseases

MAJOR ARTICLE



Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study

José M. Gatell,¹ Lambert Assmann,² Gianni Magli,³ Laura Waters,⁴ Margaret Johnson,⁵ Peter Domingo,⁶ Julia Fox,⁷ Elinchen Martinez,⁸ Hans-Jürgen Stellbrink,⁹ Giovanni Guaraldi,¹⁰ Mar Masia,¹¹ Mark Gompels,¹² Stéphane de Wit,¹³ Eric Florence,¹⁴ Stefan Essel,¹⁵ François Raff,¹⁶ Christoph Stephan,¹⁷ Juergen Rockstroh,¹⁸ Andrea Giacometti,¹⁹ Jaime Vera,²⁰ José Ignacio Bernadina,²¹ Alan Winston,²² Maria Saunoy,²³ Julian Greig,²⁴ Christian Katlama,²⁵ and Anton L. Pashankov,²⁶ for the European Network for AIDS Treatment 022 (NEAT022 Study Group)

¹Hospital Clinic/Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona and IIV HealthCare, Spain; ²Unité nationale de la santé et de la recherche médicale (INSERM), Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Unité Médecine pour la Recherche Scientifique 1101, Paris, France; ³Chicoise and Westminster Hospital and St. Dunstons AIDS Unit, Westminster Medical Centre and Royal Free Hospital, London, United Kingdom; ⁴Hospital de San Pau, Barcelona, Spain; ⁵York and St. Thomas' Hospital, London, United Kingdom; ⁶Infektionskrankheiten Spezialambulanz, Hamburg, Germany; ⁷University of Malaga and Regio Emilia, Malaga, Italy; ⁸Hospital de Elche, Spain; ⁹Southmead Hospital, Bristol, United Kingdom; ¹⁰Saint Pierre Hospital, Université libre de Bruxelles, Brussels, and ¹¹Institut of Tropical Medicine, Antwerp, Belgium; ¹²Universitätsklinikum, Essen, Germany; ¹³Infectious Diseases University Hospital and Centre of Investigation Clinique, Unité d'Investigation Clinique 1413 INSERM, Centre Hospitalier Universitaire Nantes, France; ¹⁴Clotilde de Couëtou Université, Frankfurt, and ¹⁵Medizinische Klinik und Poliklinik, Bonn, Germany; ¹⁶Hospital Luigi Sacco, Milan, Italy; ¹⁷Global Health and Infections, Brighton and Sussex Medical School, United Kingdom; ¹⁸Hospital La Paz, Madrid, Spain; ¹⁹St. Mary's Hospital, London, United Kingdom; ²⁰Hospital de Huelva, Huelva, Spain; and ²¹Hospital St Louis, and ²²Trinité-Saguenay Hospital, Paris, France

Ongoing Trials

WISARD

: SWItch Study mutAtion Rilpivirine Dolutgravir

An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with dtg/rpv fdc in antiretroviral treatment-experienced hiv-1 infected subjects virologically suppressed with nrtis resistance mutation k103n.

Sponsored By

neatid
The European treatment network for HIV, hepatitis and global infectious diseases

Funded By


ViiV
Healthcare

Status: Recruitment Closed at 140 patients

Sites: 34

Countries: 7

Posters: e-poster at IAS 2021



Ongoing Trials



REPRIEVE

Randomized Trial to Prevent Vascular Events in HIV

A phase 3 study evaluating the effect of pitavastatin to prevent cardiovascular events in hiv-1 infected individuals

Sponsored By

neatid
The European treatment network for HIV, hepatitis and global infectious diseases

Funded By

 MASSACHUSETTS
GENERAL HOSPITAL

Status: Recruitment Closed at 213 patients

Sites: 13

Countries: 1



Recruiting Trials

L A P T O P

The **L**Ate **P**resenter **T**reatment **O**Ptimisation Study

An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease

Sponsored By

neatid
The European treatment
network for HIV, hepatitis
and global infectious diseases

Funded By

 **GILEAD**



Status: In Active Recruitment

Target: 450 Patients

Sites: 43 and counting

Countries: 10 and counting

In Protocol Development

FOST Switch

Evaluating efficacy and convenience of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options.

Status: In Protocol Development

Sponsored By

neatid | The European treatment network for HIV, hepatitis and global infectious diseases

Funded By

ViiV
Healthcare

HIV Real World Data Observational Studies

Prof Cristina Mussini

Chief Investigator of COMBINE-2

Ongoing Studies



COMBINE-2

Real-world evidence for effectiveness of Two Drug Regimen, Antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitor

Sponsored and Funded By



COMBINE-2


Status: Recruitment Closed at 773 patients

Sites: 26

Countries: 7

Posters: e-poster at EACS 2021

PE2/48



Recruiting Studies

DOLOMITE

A multi- site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women

Sponsored By Funded By



In Collaboration With



The European treatment network for HIV, hepatitis and global infectious diseases

DOLOMITE

Status: In Active Recruitment


Target: 200 Patients

Sites: 22

Countries: 8



In Set Up



C2C

Cabotegravir + Rilpivirine Long Acting (LA) Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance

Sponsored and Funded By



C2C

Status: In set up

Target: 1000 Patients

Expected Sites: 47

Expected Countries: 9

In Set Up

PROMISE

*A Prospective and Retrospective, Observational
Multicentre
Ibalizumab Study of Efficacy*

Sponsored and Funded By



PROMISE

Status: In set up

Target: 230 cases and 700 controls

Expected Sites: 50

Expected Countries: 14

All Things COVID


Prof Francois Raffi

Member of the Clinical Trials Committee

Closed

GS-US-540-5807

A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19



Sponsored and Funded By



GS-US-540-5807


Status: Recruitment Closed at 1041 Patients

Sites: 5

Countries: 3

Posters: e-poster at EACS 2021

Ongoing



PIONEER

A Randomised Controlled Trial of Early Intervention in Patients Hospitalised with COVID-19: Favipiravir versus Standard Of Care

Sponsored By


Chelsea and Westminster Hospital
NHS Foundation Trust



The European treatment network for HIV, hepatitis and global infectious diseases

Funded By



PIONEER

Status: Fully Recruited at 502 patients

Sites: 3

Countries: 6




Ongoing

COVID-19 HIV CO-INFECTION DASHBOARD

All reports are based on the latest real time data submitted by participating sites.

Europe Total Report




HIV- COVID Dashboard

Title: COVID-19 HIV CO-INFECTION DASHBOARD


COVID-19 HIV Co-Infections Cumulative Total

Data from all global participating sites



Total Cumulative Hospitalisations

Data from all global participating sites



Sponsored and Funded By

neatid

The European treatment network for HIV, hepatitis and global infectious diseases

HIV COVID Dashboard

Status: Open

Sites: 73

Countries: 19 input and 30 signed up

Posters: e-poster at EACS 2021

The COVID-19 HIV CO-INFECTION DATA DASHBOARD

Behrens GMN¹, De Wit S², Vella S³, Dedes N⁴, Babiker A⁵, Brooks C⁶, Hudson M⁷, Honour H⁸, Pozniak A⁹,
Dashboard contributors¹⁰

Background: NEAT ID set up a simple web-based dashboard collecting data on HIV⁺ who were infected with SARS-CoV-2 and the number hospitalised and deaths.

Method: The Dashboard was opened in February 2020 to the network of NEAT ID Foundation members and the wider global audience via www.neat-id.org. The data was collected cumulatively over time and included the number of HIV positive patients that the site locked after, how many cases of Covid-19 or suspected Covid-19 infection recorded, any hospitalisations and subsequent deaths.



Figure 1. Cumulative numbers. From patients with Co-infection over time from all contributing sites




Figure 2. COVID-19 cases and outcomes. There were 1530 cases of COVID-19 HIV Co-infection reported up to May 2021 with 529 Hospitalizations and 100 Deaths. In Europe there were 1486, with 478 Hospitalizations and 89 Deaths reported

Conclusions: No large and disproportionate levels of Covid-19 related deaths were reported in PHIV across the network. The dashboard was the beginning of the ongoing case control HIV CoCo Study, which aims at identifying risk factors for severe Covid-19 in HIV positive patients.

¹ Hannover Medical School Hannover, Germany,
² Cardiff University, Cardiff, Wales, United Kingdom,
³ F. Icahn School of Medicine at Mount Sinai, New York, USA,
⁴ Humberstone Hospital, Lincoln, UK,
⁵ South London and Maudsley Hospital, London, UK,
⁶ Research Organisation (RO) Ltd, London, UK,
⁷ Chelsea and Westminster Hospital, London, UK,
⁸ COVID-19 Research Unit, London, UK,
⁹ COVID-19 Research Unit, London, UK,
¹⁰ COVID-19 Research Unit, London, UK

PE4/44

Results: The data presented are from 73 global submitting sites, 17 From Europe plus 6 from Canada, South America, South Africa, and India.




Figure 3. COVID-19 cases and outcomes over time. The number of deaths over time was constant and occurred in 6.1% of all those diagnosed and 18.9% of those hospitalised

neat id The European treatment network for HIV hepatitis and other infectious diseases

Ongoing

909Rem



A multi-centre, multi-country retrospective cohort study to evaluate the clinical outcomes in adults with covid-19 who have been treated with remdesivir.

Sponsored By

Funded By

neatid | The European treatment network for HIV, hepatitis and global infectious diseases



909 REM

Status: Fully Recruited at 401 patients



Sites: 12

Countries: 5

Posters:

E-poster ID week

2 x E-Poster EACS 2021



In Set Up

HIV CoCo

HIV-1 & Coronavirus-Coinfection in Europe

Morbidity & Risk Factors of COVID-19 in People Living With HIV.

Sponsored and Funded By

neatid
The European treatment
network for HIV, hepatitis
and global infectious diseases

Part Funded By

 GILEAD

HIV CoCo

Status: In set up

Target: 2000 (500 Cases and 1500 controls)

Expected Sites: 30

Expected Countries: 8

Panel Session

Moderator: Prof Anton Pozniak

**Panel: Nikos Dedes,
Prof Justyna Kowalska,
Prof Esteban Martinez**

Integration Grants

Prof Jurgen Rockstroh

Integration Grant 2021

- NEAT ID will offer up to **3 grants up to €100 each**, in competitive funding in research programs across Europe in 2021.
- NEAT ID's Integration Grant Programme encourages submissions of sub-studies (trials) relating to ongoing NEAT ID Studies
- **Deadline is Monday 10th January at 5pm GMT**
- We look forward to reading your submissions

NEAT ID Thank You

EACS London 2021
29th October